



Wattanosoth
Cancer Registry
2018





Wattanosoth Cancer Registry **2018**

Table of CONTENTS

Message from Director	2
Cancer Registry 2018 : Abstract	3
Annual Cancer Registry 2018	4
<i>Distribution of All Cancer by Age and Gender, The Top 10 Leading Site of Cancer, Patient Category of All Cancer, Method of Diagnosis, Staging, Type of Treatment, Patient Follow up, Patient Nationality, The Top 10 Leading Site of Thai Patient Cancer, The Top 10 Leading Site of Non-Thai Patient Cancer</i>	
Review of Breast Cancer	17
Review of Lung Cancer	22
Review of Colorectal Cancer	27
Review of Prostate Cancer	32
Review of Thyroid Cancer	37
Hematologic Malignancies 2018	42
Age Distribution in All Male Cancer Number of Case	58
Age Distribution in All Female Cancer Number of Case	60
Breast Cancer Survival rate	63
Colorectal Cancer Survival rate	66
Lung Cancer Survival rate	71



Message from Director



Bangkok cancer hospital Wattanosoth is the only one private comprehensive cancer center hospital in Thailand. We are under the Bangkok Dusit Medical Services Public Company Limited (BDMS), which established a new subsidiary of the company under network healthcare group in Thailand. Recently, BDMS has put every effort to lever up our hospital to be center of excellence (CoE) in cancer. Cancer registry is one of our priorities for developing our network and improvement of our cancer services.

This Wattanosoth cancer registry report is aimed to be the source of cancer patient data in hospital based for building capacity of cancer care in our services. Demographic trends that favor our growth strategy with its focus on value and quality. Rising populations, ageing and expanding middle classes are fueling demand for more and better cancer care services and products.

Our report in international patients have shown similar growth levels to previous years. These results confirm the further strengthening of our position in the steadily growing and evolving cancer care to international standard. Wattanosoth Hospital and the Faculty of Medicine Siriraj Hospital became “Sister Institutes” of MD Anderson Cancer Center under Global Academic Program.

We put every effort to improve our cancer care program in both academic-based and value based aspects. Technical innovation, consolidation and de-regulation are transforming the patient journeys with the increasing need for large scale technology and innovation platforms. Then, our major service trends as greater health and lifestyle awareness, precision medicine, values based care and quality of life.

A handwritten signature in black ink, appearing to read 'J. Khuhaprema'.

(Visiting Prof.Dr.Thiravud Khuhaprema)
Hospital Director of Wattanosoth Cancer Hospital



Cancer Registry 2018 :

Abstract

The total of new cases diagnosed as a malignancy at Bangkok Hospital Headquarter (BHQ) is 2,088 cases (Tumor registry is 1,964 cases and Hematologic malignant is 124 cases). There was a little bit increased in the total number as compared to 2,056 cases in 2017.

The sex ratio is 1:1 This age distribution has not changed since the year 2017. Patients who are between 45-69 y/o are the majority accounting for more than half of the total. The average age in male patients is 55-74 y/o. which is slightly older than the female age of 45-64 y/o.

Top 5 malignancies are:

- | | |
|---|----------------------------|
| 1) Breast (included DCIS) - 24.04 percent | 4) Prostate - 7.81 percent |
| 2) Lung - 10.44 percent | 5) Thyroid - 6.51 percent |
| 3) Colorectal - 9.20 percent | |

The trend for the top 5 malignancies has not changed over the past 10 years (2006-2017). For the past 10 years the top 5 have been: **Breast, Colorectal, Lung, Liver and Hepatobiliary and Head & Neck cancer**. However, when compared to last year, the overall number of cases in Breast cancer increased significantly by 1.41 percent, Lung cancer decreased by 9.16 percent, Colorectal cancer decreased by 6.34 percent, Prostate cancer increased by 46.84 percent and Thyroid cancer decreased by 0.72 percent.

The results of overall staging of patients who received treatment at Bangkok Hospital Headquarter (BHQ) are: Stage 0 3.49 percent, Stage I is 22.41 percent, Stage II is 22.86 percent, Stage III is 21.17 percent, and Stage IV is 20.61 percent. Unspecified stage (due to lack of pertinent information) is 8.56 percent. And in cases of Brain cancer has no stage grouping applies in AJCC Staging manual is 0.90 percent. All results are similar to 2017 staging results.

Analysis of the primary treatments modalities indicates that Surgery continues to be the majority (21 percent), followed by Radiation therapy (13 percent), Chemotherapy (5 percent), Radioactive Iodine Therapy (RAI) (2 percent) and Interventional treatment (2 percent)

Patients who are still living after diagnosis or treatment in 2018 is 97 percent and patients who have died with cancer as the cause are 3 percent. At this time no patients receiving treatment have been lost to follow-up.

Ratio of Thai to non-Thai patients is 1:1 in year 2018 equal to the year 2017. The top 5 rankings of non-Thai patients are: Myanmar, Cambodia, Bangladesh, Oman and Kuwait respectively.

The Top 5 malignancies of Thai patients are:

- | | |
|---|----------------------------|
| 1) Breast (included DCIS) - 30.36 percent | 4) Thyroid - 6.58 percent |
| 2) Lung - 12.61 percent | 5) Prostate - 6.36 percent |
| 3) Colorectal - 10.16 percent | |

The Top 5 malignancies of non-Thai patients are:

- | | |
|---|---|
| 1) Breast (included DCIS) - 19.30 percent | 4) Colorectal - 8.47 percent |
| 2) Prostate - 8.89 percent | 5) Liver and Hepatobiliary - 7.72 percent |
| 3) Lung - 8.81 percent | |

It is the fifth time BHQ can follow the patients for 5 years and report the 5-years survival. We have shown and discussed the data of those survivors of top 3 cancers which are Breast, Lung and Colorectal in separated chapters.

WATTANOSOTH ANNUAL CANCER REGISTRY 2018



DISTRIBUTION OF ALL CANCER BY AGE AND GENDER

(EXCLUDED HEMATOLOGIC MALIGNANCIES)

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	3	0.33	3	0.28	6	0.31
20 - 24	2	0.22	9	0.84	11	0.56
25 - 29	12	1.34	31	2.91	43	2.19
30 - 34	19	2.12	55	5.16	74	3.77
35 - 39	27	3.01	95	8.91	122	6.21
40 - 44	40	4.45	87	8.16	127	6.47
45 - 49	60	6.68	132	12.38	192	9.78
50 - 54	92	10.24	145	13.60	237	12.07
55 - 59	112	12.47	149	13.98	261	13.29
60 - 64	132	14.70	134	12.57	266	13.54
65 - 69	149	16.59	84	7.88	233	11.86
70 - 74	111	12.36	52	4.88	163	8.30
75 - 79	76	8.46	46	4.32	122	6.21
80 - 84	44	4.90	19	1.78	63	3.21
85 - 89	13	1.45	19	1.78	32	1.63
90 - 94	5	0.56	6	0.56	11	0.56
95 +	1	0.11	0	0.00	1	0.05
Total	898	100.00	1,066	100.00	1,964	100.00

DISTRIBUTION OF ALL CANCER BY AGE AND GENDER

2017




THE TOP 10 LEADING SITE OF CANCER IN BANGKOK HOSPITAL HEADQUARTER


Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	2	0.21	500	44.92	502	24.04
C33-C34	Lung	135	13.85	83	7.46	218	10.44
C18-C20	Colorectal	123	12.62	69	6.20	192	9.20
C61	Prostate	163	16.72	0	0.00	163	7.81
C73	Thyroid gland	38	3.90	98	8.81	136	6.51
C22-C24	Liver and Hepatobiliary	100	10.26	29	2.61	129	6.18
C00-C14	Head & Neck	75	7.69	30	2.70	105	5.03
C81-C85	Lymphoma	50	5.13	32	2.88	82	3.93
C53	Cervix	0	0.00	60	5.39	60	2.87
C16	Stomach	32	3.28	20	1.80	52	2.49

TOP 10 CANCER FOR ALL GENDER

All Patient




2017




OVERALL CANCER

TOP 10 CANCER IN MALE

Male




2017




TOP 10 CANCER IN FEMALE

Female




2017




PATIENT CATEGORY OF ALL CANCER IN BANGKOK HOSPITAL HEADQUARTER

Patient treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Treatment in BHQ	384	42.76	504	47.28	888	45.21
Treatment outside BHQ	514	57.24	562	52.72	1,076	54.79
Total	898	100.00	1,066	100.00	1,964	100.00




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


All Patient



Male



Female



Stage 0 = Carcinoma in situ

None stage = In case of Brain tumor

Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	120	13.36	137	12.85	257	13.09
RT only	94	10.47	146	13.70	240	12.22
CT only	30	3.34	23	2.16	53	2.70
Targeted therapy	3	0.33	2	0.19	5	0.25
Hormonal therapy	1	0.11	0	0.00	1	0.05
Intervention	25	2.78	8	0.75	33	1.68
Nuclear medicine	14	1.56	34	3.19	48	2.44
Concurrent chemoradiation	15	1.67	9	0.84	24	1.22
SUR.+RT	9	1.00	12	1.13	21	1.07
SUR.+CT	23	2.56	44	4.13	67	3.41
SUR.+Im	1	0.11	0	0.00	1	0.05
SUR.+H	1	0.11	14	1.31	15	0.76
SUR.+T	1	0.11	1	0.09	2	0.10
SUR.+I	2	0.22	0	0.00	2	0.10
SUR.+N	8	0.89	6	0.56	14	0.71
SUR.+Concurrent CT-RT	9	1.00	4	0.38	13	0.66
RT+Concurrent CT-RT	0	0.00	3	0.28	3	0.15
CT+Concurrent CT-RT	2	0.22	1	0.09	3	0.15
RT+T	0	0.00	1	0.09	1	0.05
RT+CT	6	0.67	6	0.56	12	0.61
RT+H	2	0.22	2	0.19	4	0.20
RT+I	1	0.11	0	0.00	1	0.05
CT+H	1	0.11	1	0.09	2	0.10
CT+T	1	0.11	1	0.09	2	0.10
CT+I	0	0.00	2	0.19	2	0.10
Concurrent CT-RT+Im	1	0.11	0	0.00	1	0.05
I+T	1	0.11	0	0.00	1	0.05
SUR.+RT+CT	7	0.78	22	2.06	29	1.48

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.+RT+H	0	0.00	7	0.66	7	0.36
SUR.+CT+H	0	0.00	6	0.56	6	0.31
SUR.+CT+I	2	0.22	0	0.00	2	0.10
SUR.+CT+Concurrent CT-RT	1	0.11	1	0.09	2	0.10
SUR.+RT+CT+H	0	0.00	9	0.84	9	0.46
SUR.+RT+CT+T	0	0.00	1	0.09	1	0.05
SUR.+CT+T+H	0	0.00	1	0.09	1	0.05
SUR.+RT+Concurrent CT-RT	1	0.11	0	0.00	1	0.05
RT+I+T	1	0.11	0	0.00	1	0.05
CT+Concurrent CT-RT+Im	1	0.11	0	0.00	1	0.05
Investigation	89	9.91	125	11.73	214	10.90
Supportive	2	0.22	1	0.09	3	0.15
PET/CT	144	16.04	137	12.85	281	14.31
Bone scan	85	9.47	81	7.60	166	8.45
2 nd Opinion	194	21.60	213	19.98	407	20.72
TBS scan	0	0.00	5	0.47	5	0.25
Total	898	100.00	1,066	100.00	1,964	100.00

SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy


H (Hormone) = Hormonal therapy

T = Targeted therapy

I = Intervention


Im = Immunotherapy

TYPE OF PRIMARY MANAGEMENT (ALL PATIENT)




PATIENT FOLLOW UP

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	867	96.55	1,045	98.03	1,912	97.35
Dead	31	3.45	21	1.97	52	2.65
Total	898	100.00	1,066	100.00	1,964	100.00



REFERRING HOSPITAL



BHQ = Consult from Bangkok General Hospital

Samitivej Group = Samitivej Hospital Group

BNH = BNH Hospital

Paolo Group = Paolo Hospital Group

BCH = Bangkok Hospital Chanthaburi

RPH = Royal Phnom Penh Hospital

BUD = Bangkok Hospital Udon

BHH = Bangkok Hospital Hatyai

BPR = Bangkok Hospital Phetchaburi

BSI = Bangkok Siriraj Hospital

BHP = Bangkok Hospital Pakchong

BSR = Bangkok Hospital Surat

PYT Group = Payathai Hospital Group

BPH = Bangkok Hospital Pattaya

BPK = Bangkok Hospital Phuket

BHN = Bangkok Hospital Hua Hin

BRH = Bangkok Hospital Rayong

BKH = Bangkok Hospital Ratchasima

BSH = Bangkok Hospital Samui

BCM = Bangkok Hospital Chiangmai


BSN = Bangkok Hospital Sanamchan

BKN = Bangkok Hospital Khonkhan


BMR = Bangkok Hospital Muangraj

PATIENT NATIONALITY

TOTAL PATIENT NATIONALITY



NON-THAI PATIENT NATIONALITY




THE TOP 10 LEADING SITE OF THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER


Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	0	0.00	272	48.40	272	30.36
C33-C34	Lung	61	18.26	52	9.25	113	12.61
C18-C20	Colorectal	58	17.37	33	5.87	91	10.16
C73	Thyroid gland	10	2.99	49	8.72	59	6.58
C61	Prostate	57	17.07	0	0.00	57	6.36
C81-C85	Lymphoma	18	5.39	20	3.56	38	4.24
C22-C24	Liver and Hepatobiliary	30	8.98	7	1.25	37	4.13
C00-C14	Head & Neck	20	5.99	12	2.14	32	3.57
C53	Cervix	0	0.00	27	4.80	27	3.01
C54	Endometrium	0	0.00	21	3.74	21	2.34

TOP 10 CANCER OF THAI PATIENT ALL GENDER

All Gender




2017




OVERALL CANCER

TOP 10 CANCER OF THAI PATIENT IN MALE

Male




2017




TOP 10 CANCER OF THAI PATIENT IN FEMALE

Female



2017




THE TOP 10 LEADING SITE OF NON-THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER


Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	2	0.31	228	41.38	230	19.30
C61	Prostate	106	16.54	0	0.00	106	8.89
C33-C34	Lung	74	11.54	31	5.63	105	8.81
C18-C20	Colorectal	65	10.14	36	6.53	101	8.47
C22-C24	Liver and Hepatobiliary	70	10.92	22	3.99	92	7.72
C73	Thyroid gland	28	4.37	49	8.89	77	6.46
C00-C14	Head & Neck	55	8.58	18	3.27	73	6.12
C81-C85	Lymphoma	32	4.99	12	2.18	44	3.69
C16	Stomach	25	3.90	13	2.36	38	3.19
C25	Pancreas	21	3.28	13	2.36	34	2.85

TOP 10 CANCER OF NON-THAI PATIENT ALL GENDER

All Gender




2017




OVERALL CANCER

TOP 10 CANCER OF NON-THAI PATIENT IN MALE

Male




2017




TOP 10 CANCER OF NON-THAI PATIENT IN FEMALE

Female



2017



BREAST CANCER : PATHOLOGY


Tumor site		Number
50.0	Nipple	10
50.1	Central portion of breast	4
50.2	Upper-inner quadrant of breast	33
50.3	Lower-inner quadrant of breast	19
50.4	Upper-outer quadrant of breast	107
50.5	Lower-outer quadrant of breast	18
50.6	Axillary tail	1
50.8	Overlapping lesion of breast	25
50.9	Breast, NOS	285
Total		502

Pathology Report		Number
8000/3	Malignant neoplasm	134
8010/3	Carcinoma, NOS	4
8140/3	Adenocarcinoma, NOS	2
8211/3	Tubular carcinoma	1
8480/3	Mucinous carcinoma	3
8480/3	Mucinous adenocarcinoma	1
8500/2	Ductal carcinoma in situ	49
8500/3	Infiltrating ductal carcinoma	287
8507/3	Invasive micropapillary carcinoma	2
8520/2	Lobular carcinoma in situ	3
8520/3	Invasive lobular carcinoma	11
8522/3	Infiltrating duct and lobular carcinoma	2
8523/3	Infiltrating duct and mucinous carcinoma	1
8720/3	Malignant melanoma	1
9020/3	Malignant phyllodes tumor	1
Total		502


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	9	1.80	9	1.79
30 - 34	0	0.00	23	4.60	23	4.58
35 - 39	0	0.00	52	10.40	52	10.36
40 - 44	0	0.00	56	11.20	56	11.16
45 - 49	0	0.00	82	16.40	82	16.33
50 - 54	0	0.00	78	15.60	78	15.54
55 - 59	0	0.00	73	14.60	73	14.54
60 - 64	1	50.00	52	10.40	53	10.56
65 - 69	1	50.00	30	6.00	31	6.18
70 - 74	0	0.00	17	3.40	17	3.39
75 - 79	0	0.00	17	3.40	17	3.39
80 - 84	0	0.00	2	0.40	2	0.40
85 - 89	0	0.00	5	1.00	5	1.00
90 - 94	0	0.00	4	0.80	4	0.80
95 +	0	0.00	0	0.00	0	0.00
Total	2	100.00	500	100.00	502	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Breast cancer from other Hospital but no documentation of diagnosis

STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Stage 0 = Carcinoma in situ

Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	0	0.00	64	26.56	64	26.45
RT only	0	0.00	87	36.10	87	35.95
CT only	0	0.00	6	2.49	6	2.48
SUR.+RT	0	0.00	4	1.66	4	1.65
SUR.+CT	0	0.00	19	7.88	19	7.85
SUR.+H	0	0.00	13	5.39	13	5.37
RT+CT	0	0.00	1	0.41	1	0.41
RT+H	0	0.00	2	0.83	2	0.83
CT+H	1	100.00	1	0.41	2	0.83
SUR.+RT+CT	0	0.00	20	8.30	20	8.26
SUR.+RT+H	0	0.00	7	2.90	7	2.89
SUR.+CT+H	0	0.00	6	2.49	6	2.48
SUR.+RT+CT+H	0	0.00	10	4.15	10	4.13
SUR.+CT+T+H	0	0.00	1	0.41	1	0.41
Total	1	100.00	241	100.00	242	100.00



SUR. = Surgery ,
CT = Chemotherapy ,
T = Targeted therapy

RT = External radiation therapy
H (Hormone) = Hormonal therapy

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	1	100.00	240	99.59	241	99.59
Dead	0	0.00	1	0.41	1	0.41
Total	1	100.00	241	100.00	242	100.00

Dead

0%



Alive

100%

LUNG CANCER : PATHOLOGY


Tumor site		Number
34.0	Main bronchus	2
34.1	Upper lobe, lung	72
34.2	Middle lobe, lung	7
34.3	Lower lobe, lung	36
34.8	Overlapping lesion of lung	2
34.9	Lung, NOS	99
Total		218

Pathology Report		Number
M8000/3	Malignant neoplasm	67
M8010/3	Carcinoma, NOS	5
M8012/3	Large cell carcinoma, NOS	2
M8013/3	Large cell neuroendocrine carcinoma	2
M8041/3	Small cell carcinoma, NOS	7
M8046/3	Non small cell carcinoma	16
M8070/3	Squamous cell carcinoma, NOS	9
M8082/3	Lymphoepithelioma-like carcinoma	1
M8140/3	Adenocarcinoma, NOS	94
M8144/3	Adenocarcinoma, intestinal type	1
M8246/3	Neuroendocrine carcinoma	3
M8260/3	Papillary adenocarcinoma	3
M8480/3	Mucinous adenocarcinoma	1
M8480/3	Colloid adenocarcinoma	1
M8550/3	Acinar cell carcinoma	4
M8801/3	Spindle cell sarcoma	1
M9050/3	Mesothelioma, malignant	1
Total		218


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	1	1.20	1	0.46
30 - 34	1	0.74	1	1.20	2	0.92
35 - 39	2	1.48	1	1.20	3	1.38
40 - 44	5	3.70	1	1.20	6	2.75
45 - 49	7	5.19	2	2.41	9	4.13
50 - 54	15	11.11	15	18.07	30	13.76
55 - 59	14	10.37	9	10.84	23	10.55
60 - 64	28	20.74	15	18.07	43	19.72
65 - 69	21	15.56	13	15.66	34	15.60
70 - 74	19	14.07	8	9.64	27	12.39
75 - 79	19	14.07	8	9.64	27	12.39
80 - 84	4	2.96	5	6.02	9	4.13
85 - 89	0	0.00	3	3.61	3	1.38
90 - 94	0	0.00	1	1.20	1	0.46
95 +	0	0.00	0	0.00	0	0.00
Total	135	100.00	83	100.00	218	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Lung cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	6	13.64	6	20.00	12	16.22
RT only	18	40.91	14	46.67	32	43.24
CT only	8	18.18	0	0.00	8	10.81
Targeted therapy	3	6.82	1	3.33	4	5.41
Concurrent chemoradiation	2	4.55	0	0.00	2	2.70
SUR.+RT	1	2.27	2	6.67	3	4.05
SUR.+CT	1	2.27	3	10.00	4	5.41
SUR.+T	0	0.00	1	3.33	1	1.35
SUR.+Concurrent CT-RT	0	0.00	1	3.33	1	1.35
Concurrent chemoradiation+Immunotherapy	1	2.27	0	0.00	1	1.35
RT+T	0	0.00	1	3.33	1	1.35
RT+CT	2	4.55	1	3.33	3	4.05
SUR.+RT+CT	1	2.27	0	0.00	1	1.35
SUR.+CT+Concurrent CT-RT	1	2.27	0	0.00	1	1.35
Total	44	100.00	30	100.00	74	100.00



SUR. = Surgery


RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	39	88.64	29	96.67	68	91.89
Dead	5	11.36	1	3.33	6	8.11
Total	44	100.00	30	100.00	74	100.00



COLORECTAL CANCER : PATHOLOGY


Tumor site		Number
C18.0	Cecum colon	9
C18.2	Ascending colon	12
C18.3	Hepatic flexure of colon	1
C18.4	Transverse colon	10
C18.5	Splenic flexure of colon	3
C18.6	Descending colon	10
C18.7	Sigmoid colon	45
C18.9	Colon, NOS	35
C19.9	Rectosigmoid colon	14
C20.9	Rectum	53
Total		192

Pathology Report		Number
M8000/3	Malignant neoplasm	57
M8140/3	Adenocarcinoma	120
M8144/3	Adenocarcinoma, intestinal type	3
M8480/3	Mucinous adenocarcinoma	8
M8480/3	Mucinous carcinoma	1
M8490/3	Signet ring cell adenocarcinoma	3
Total		192


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	1	1.45	1	0.52
25 - 29	3	2.44	2	2.90	5	2.60
30 - 34	6	4.88	3	4.35	9	4.69
35 - 39	2	1.63	7	10.14	9	4.69
40 - 44	3	2.44	2	2.90	5	2.60
45 - 49	4	3.25	5	7.25	9	4.69
50 - 54	12	9.76	5	7.25	17	8.85
55 - 59	19	15.45	13	18.84	32	16.67
60 - 64	18	14.63	11	15.94	29	15.10
65 - 69	22	17.89	10	14.49	32	16.67
70 - 74	14	11.38	4	5.80	18	9.38
75 - 79	10	8.13	1	1.45	11	5.73
80 - 84	6	4.88	5	7.25	11	5.73
85 - 89	3	2.44	0	0.00	3	1.56
90 - 94	1	0.81	0	0.00	1	0.52
95 +	0	0.00	0	0.00	0	0.00
Total	123	100.00	69	100.00	192	100.00

■ Male ■ Female



METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	30	48.39	7	28.00	37	42.53
RT only	8	12.90	4	16.00	12	13.79
CT only	5	8.06	2	8.00	7	8.05
Intervention	1	1.61	0	0.00	1	1.15
Concurrent chemoradiation	3	4.84	2	8.00	5	5.75
SUR.+CT	7	11.29	6	24.00	13	14.94
SUR.+I	1	1.61	0	0.00	1	1.15
SUR.+Concurrent CT-RT	1	1.61	1	4.00	2	2.30
CT+Concurrent CT-RT	0	0.00	1	4.00	1	1.15
RT+CT	0	0.00	1	4.00	1	1.15
CT+T	1	1.61	0	0.00	1	1.15
CT+I	2	3.23	0	0.00	2	2.30
SUR.+RT+CT	2	3.23	0	0.00	2	2.30
SUR.+CT+I	1	1.61	0	0.00	1	1.15
SUR.+CT+Concurrent CT-RT	0	0.00	1	4.00	1	1.15
Total	62	100.00	25	100.00	87	100.00



SUR. = Surgery


RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	57	95.00	25	92.59	82	94.25
Dead	3	5.00	2	7.41	5	5.75
Total	60	100.00	27	100.00	87	100.00




PROSTATE CANCER : PATHOLOGY

Tumor site		Number
C61.9	Prostate	163
Total		163


Pathology Report		Number
M8000/3	Malignant neoplasm	65
M8140/3	Adenocarcinoma, NOS	46
M8550/3	Acinar adenocarcinoma	48
M8550/3	Acinar carcinoma	4
Total		163

AGE AND GENDER

Age	Male	
	Number	Percent
15 - 19	0	0.00
20 - 24	0	0.00
25 - 29	0	0.00
30 - 34	0	0.00
35 - 39	0	0.00
40 - 44	1	0.61
45 - 49	2	1.23
50 - 54	8	4.91
55 - 59	11	6.75
60 - 64	30	18.40
65 - 69	37	22.70
70 - 74	31	19.02
75 - 79	18	11.04
80 - 84	17	10.43
85 - 89	6	3.68
90 - 94	2	1.23
95 +	0	0.00
Total	163	100.00




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male	
	Number	Percent
SUR. only	18	35.29
RT only	20	39.22
CT only	2	3.92
Hormonal therapy	1	1.96
SUR.+RT	2	3.92
SUR.+CT	3	5.88
SUR.+H	1	1.96
RT+CT	1	1.96
RT+H	2	3.92
SUR.+RT+CT	1	1.96
Total	51	100.00



SUR. = Surgery

RT = External radiation therapy


CT = Chemotherapy

T = Targeted therapy

I = Intervention

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male	
	Number	Percent
Alive	50	98.04
Dead	1	1.96
Total	51	100.00



THYROID CANCER : PATHOLOGY


Tumor site		Number
C73.9	Thyroid gland	136
Total		136

Pathology Report		Number
M8000/3	Malignant neoplasm	19
M8260/3	Papillary carcinoma of thyroid	80
M8290/3	Hurthle cell carcinoma	2
M8330/3	Follicular carcinoma	2
M8340/3	Papillary carcinoma follicular variant	24
M8341/3	Papillary microcarcinoma	7
M8345/3	Medullary carcinoma of thyroid	2
Total		136


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	1	1.02	1	0.74
20 - 24	1	2.63	4	4.08	5	3.68
25 - 29	2	5.26	13	13.27	15	11.03
30 - 34	2	5.26	14	14.29	16	11.76
35 - 39	7	18.42	17	17.35	24	17.65
40 - 44	2	5.26	7	7.14	9	6.62
45 - 49	7	18.42	15	15.31	22	16.18
50 - 54	4	10.53	8	8.16	12	8.82
55 - 59	2	5.26	5	5.10	7	5.15
60 - 64	5	13.16	7	7.14	12	8.82
65 - 69	3	7.89	3	3.06	6	4.41
70 - 74	2	5.26	2	2.04	4	2.94
75 - 79	1	2.63	2	2.04	3	2.21
80 - 84	0	0.00	0	0.00	0	0.00
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	38	100.00	98	100.00	136	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Head and Neck cancer from other Hospital but no document of Pathology


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	2	8.00	13	24.53	15	19.23
Radioactive Iodine Therapy (RAI)	15	60.00	34	64.15	49	62.82
SUR.+Radioactive Iodine Therapy (RAI)	8	32.00	6	11.32	14	17.95
Total	25	100.00	53	100.00	78	100.00



SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	25	100.00	53	100.00	78	100.00
Total	25	100.00	53	100.00	78	100.00

Alive
100%




HEMATOLOGIC MALIGNANCIES 2018

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES

Code	Disease	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C81	Hodgkin's disease	7	9.09	6	12.77	13	10.48
C82	Follicular NHL	5	6.49	2	4.26	7	5.65
C83	Diffuse NHL	28	36.36	20	42.55	48	38.71
C84	Peripheral and cutaneous T-cell lymphoma	1	1.30	0	0.00	1	0.81
C85	Other and unspecified type of NHL	9	11.69	4	8.51	13	10.48
C90	Multiple myeloma	10	12.99	5	10.64	15	12.10
C91	Lymphoid leukemia	7	9.09	4	8.51	11	8.87
C92	Myeloid leukemia	8	10.39	6	12.77	14	11.29
D46	Myelodysplastic syndrome, NOS	2	2.60	0	0.00	2	1.61
Total		77	100.00	47	100.00	124	100.00


All Patient



DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	2	2.60	3	6.38	5	4.03
20 - 24	2	2.60	1	2.13	3	2.42
25 - 29	5	6.49	1	2.13	6	4.84
30 - 34	4	5.19	4	8.51	8	6.45
35 - 39	7	9.09	4	8.51	11	8.87
40 - 44	3	3.90	5	10.64	8	6.45
45 - 49	9	11.69	2	4.26	11	8.87
50 - 54	9	11.69	4	8.51	13	10.48
55 - 59	11	14.29	3	6.38	14	11.29
60 - 64	7	9.09	7	14.89	14	11.29
65 - 69	7	9.09	4	8.51	11	8.87
70 - 74	3	3.90	5	10.64	8	6.45
75 - 79	5	6.49	1	2.13	6	4.84
80 - 84	2	2.60	2	4.26	4	3.23
85 - 89	1	1.30	1	2.13	2	1.61
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	77	100.00	47	100.00	124	100.00

■ Male ■ Female




PATIENT NATIONALITY

Patient Nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Thai	30	38.96	29	61.70	59	47.58
Non-Thai	47	61.04	18	38.30	65	52.42
Total	77	100.00	47	100.00	124	100.00



PATIENT FOLLOW UP STATUS

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	72	93.51	44	93.62	116	93.55
Dead	5	6.49	3	6.38	8	6.45
Total	77	100.00	47	100.00	124	100.00




LYMPHOMA

AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	1	2.00	3	9.38	4	4.88
20 - 24	1	2.00	1	3.13	2	2.44
25 - 29	3	6.00	1	3.13	4	4.88
30 - 34	3	6.00	3	9.38	6	7.32
35 - 39	7	14.00	3	9.38	10	12.20
40 - 44	1	2.00	3	9.38	4	4.88
45 - 49	7	14.00	0	0.00	7	8.54
50 - 54	5	10.00	2	6.25	7	8.54
55 - 59	5	10.00	1	3.13	6	7.32
60 - 64	5	10.00	4	12.50	9	10.98
65 - 69	4	8.00	4	12.50	8	9.76
70 - 74	2	4.00	4	12.50	6	7.32
75 - 79	4	8.00	0	0.00	4	4.88
80 - 84	1	2.00	2	6.25	3	3.66
85 - 89	1	2.00	1	3.13	2	2.44
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	50	100.00	32	100.00	82	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Pathology of primary organ	16	100.00	15	100.00	31	100.00
Total	16	100.00	15	100.00	31	100.00



STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information




TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiotherapy	7	43.75	4	26.67	11	35.48
Chemotherapy	9	56.25	8	53.33	17	54.84
Surgery+Chemotherapy	0	0.00	1	6.67	1	3.23
Radiotherapy+Chemotherapy	0	0.00	1	6.67	1	3.23
Stem cell transplantation	0	0.00	1	6.67	1	3.23
Total	16	100.00	15	100.00	31	100.00



PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	16	100.00	14	93.33	30	96.77
Dead	0	0.00	1	6.67	1	3.23
Total	16	100.00	15	100.00	31	100.00




MULTIPLE MYELOMA

AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	1	10.00	0	0.00	1	6.67
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	0	0.00	0	0.00	0	0.00
35 - 39	0	0.00	0	0.00	0	0.00
40 - 44	1	10.00	1	20.00	2	13.33
45 - 49	1	10.00	0	0.00	1	6.67
50 - 54	1	10.00	1	20.00	2	13.33
55 - 59	1	10.00	1	20.00	2	13.33
60 - 64	2	20.00	1	20.00	3	20.00
65 - 69	2	20.00	0	0.00	2	13.33
70 - 74	1	10.00	1	20.00	2	13.33
75 - 79	0	0.00	0	0.00	0	0.00
80 - 84	0	0.00	0	0.00	0	0.00
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	10	100.00	5	100.00	15	100.00

■ Male ■ Female



METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Pathology of primary organ	4	100.00	2	100.00	6	100.00
Total	4	100.00	2	100.00	6	100.00



TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiotherapy	1	25.00	0	0.00	1	16.67
Chemotherapy	1	25.00	0	0.00	1	16.67
Stem cell transplantation	1	25.00	2	100.00	3	50.00
Chemotherapy+Stem cell transplantation	1	25.00	0	0.00	1	16.67
Total	4	100.00	2	100.00	6	100.00

Chemotherapy+Stem cell
transplantation

17%

Stem cell transplantation

50%



Radiotherapy


16%

Chemotherapy

17%

PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	4	100.00	2	100.00	6	100.00
Dead	0	0.00	0	0.00	0	0.00
Total	4	100.00	2	100.00	6	100.00




LEUKEMIA

AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	1	6.67	0	0.00	1	4.00
25 - 29	2	13.33	0	0.00	2	8.00
30 - 34	0	0.00	1	10.00	1	4.00
35 - 39	0	0.00	1	10.00	1	4.00
40 - 44	1	6.67	1	10.00	2	8.00
45 - 49	1	6.67	2	20.00	3	12.00
50 - 54	3	20.00	1	10.00	4	16.00
55 - 59	5	33.33	1	10.00	6	24.00
60 - 64	0	0.00	2	20.00	2	8.00
65 - 69	0	0.00	0	0.00	0	0.00
70 - 74	0	0.00	0	0.00	0	0.00
75 - 79	1	6.67	1	10.00	2	8.00
80 - 84	1	6.67	0	0.00	1	4.00
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	15	100.00	10	100.00	25	100.00

■ Male ■ Female



METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Cytology	2	33.33	0	0.00	2	25.00
Pathology of primary organ	4	66.67	2	100.00	6	75.00
Total	6	100.00	2	100.00	8	100.00



TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy	2	33.33	0	0.00	2	25.00
Targeted therapy	0	0.00	1	50.00	1	12.50
Stem cell transplantation	2	33.33	0	0.00	2	25.00
Chemotherapy+Stem cell transplantation	1	16.67	1	50.00	2	25.00
Radiotherapy+Chemotherapy+Stem cell transplantation	1	16.67	0	0.00	1	12.50
Total	6	100.00	2	100.00	8	100.00

Radiotherapy+Chemotherapy+Stem cell transplantation

13%

Chemotherapy+Stem cell transplantation

25%




Chemotherapy
25%

Targeted therapy
12%

Stem cell transplantation
25%

PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	4	66.67	2	100.00	6	75.00
Dead	2	33.33	0	0.00	2	25.00
Total	6	100.00	2	100.00	8	100.00



AGE DISTRIBUTION IN ALL MALE CANCER NUMBER OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.10
C01-C02	Tongue	0	0	1	1	2	2	2	4	2	1	1	0	0	0	0	0	0	18	1.85
C03	Gum	0	0	0	0	0	0	1	0	0	0	3	0	0	0	0	0	0	4	0.41
C04	Floor of mouth	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	3	0.31
C05	Palate	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	2	0.21
C06	Other part of mouth	0	0	0	0	1	2	3	2	1	0	0	1	0	0	0	0	0	10	1.03
C07	Parotid gland	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	2	0.21
C08	Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.10
C09	Tonsil	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	4	0.41
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C11-C14	Head and Neck	1	0	2	2	4	5	2	1	5	2	3	2	0	0	0	0	0	30	3.08
C15	Esophagus	0	0	0	0	0	0	3	0	7	5	4	5	0	0	0	0	0	24	2.46
C16	Stomach	0	0	0	1	1	2	2	2	7	7	6	2	0	2	0	0	0	32	3.28
C17	Small intestine	0	0	0	0	0	0	0	1	0	2	1	0	0	0	0	0	0	4	0.41
C18-C20	Colon and Rectum	0	0	3	6	2	3	4	12	19	18	22	14	9	6	3	1	0	123	12.62
C21	Anus	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	2	0.21
C22-C24	Liver and Hepatobiliary	0	0	0	1	2	10	12	12	15	13	11	10	10	5	0	1	0	100	10.26
C25	Pancreas	0	0	0	1	0	0	4	4	5	3	7	4	2	0	1	0	0	31	3.18
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0.10
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.10
C32	Larynx	0	0	0	1	1	0	1	2	3	2	6	3	2	0	0	0	0	20	2.05
C33-C34	Lung	0	0	0	1	2	5	7	15	14	28	21	19	10	4	0	0	0	135	13.85
C37	Thymus	0	0	0	1	0	0	0	0	0	2	0	0	1	0	0	0	0	3	0.31
C38	Mediastinum	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0.21
C40-C41	Bone	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3	0.31
C43-C44	Skin	0	0	0	0	1	1	0	2	4	4	9	4	4	3	2	0	0	33	3.38
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0.21
C49	Connective tissue	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	0	4	0.41
C50	Breast	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2	0.21
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C53	Cervix	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C54	Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	3	0.31
C61	Prostate gland	0	0	0	0	0	1	2	8	11	30	37	31	18	17	6	2	0	163	16.72
C62	Testis	0	0	1	0	1	0	0	3	1	0	0	0	0	0	0	0	0	6	0.62
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.10
C64-C65	Urinary tract	0	0	0	0	1	2	4	5	7	4	0	2	3	2	0	1	0	31	3.18
C66	Ureter	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	2	0.21
C67	Bladder	0	0	0	0	1	1	1	7	4	3	6	6	4	4	1	0	1	39	4.00
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye and Adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	0	0	1	1	1	1	3	2	1	0	0	0	0	0	0	0	0	10	1.03
C72	Spinal cord and CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	1	2	2	7	2	7	4	2	5	3	2	1	0	0	0	0	38	3.90
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C75	Other and endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other and ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C79	Unknown primarysite	0	0	2	0	0	1	0	1	1	0	1	1	1	0	0	0	0	8	0.82
C81	Hodgkin's disease	1	0	1	0	0	0	1	2	0	0	0	1	0	1	0	0	0	7	0.72
C82	Follicular NHL	0	0	0	1	1	0	0	1	1	0	0	0	0	0	1	0	0	5	0.51
C83	Diffuse NHL	0	0	2	2	4	0	5	1	2	5	2	1	4	0	0	0	0	28	2.87
C84	Peripheral and cutaneous T-cell lymphoma	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.10
C85	Other and unspecified type of NHL	0	1	0	0	2	0	1	1	2	0	2	0	0	0	0	0	0	9	0.92
C90	Multiple myeloma	1	0	0	0	0	1	1	1	1	2	2	1	0	0	0	0	0	10	1.03
C91	Lymphoid leukemia	0	1	1	0	0	0	0	1	2	0	0	0	1	1	0	0	0	7	0.72
C92	Myeloid leukemia	0	0	1	0	0	1	1	2	3	0	0	0	0	0	0	0	0	8	0.82
C95	Leukemia of unspecified cell type	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
D46	Myelodysplastic syndrome	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0.21
D05	Ductal carcinoma in situ of breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
All ICD Group		5	4	17	23	34	43	69	101	123	139	156	114	81	46	14	5	1	975	100.00

AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBER OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C01-C02	Tongue	0	0	0	0	1	0	3	0	0	2	0	0	0	1	1	0	0	8	0.72
C03	Gum	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	1	0	3	0.27
C04	Floor of mouth	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.09
C05	Palate	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.09
C06	Other part of mouth	0	0	0	0	0	0	1	0	0	2	0	0	0	0	1	0	0	4	0.36
C07	Parotid gland	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.09
C08	Other and unspecified major salivary glands	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.09
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.09
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.09
C11-C14	Head and Neck	0	0	0	1	0	1	3	2	0	1	1	0	0	0	0	0	0	9	0.81
C15	Esophagus	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0.18
C16	Stomach	0	0	0	1	1	3	2	3	1	1	3	2	0	2	1	0	0	20	1.80
C17	Small Intestine	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	3	0.27
C18-C20	Colon and Rectum	0	1	2	3	7	2	5	5	13	11	10	4	1	5	0	0	0	69	6.20
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.09
C22-C24	Liver and Hepatobiliary	0	0	0	0	1	0	1	2	11	6	1	1	1	2	3	0	0	29	2.61
C25	Pancreas	1	0	0	1	0	2	1	2	0	5	3	0	2	0	0	0	0	17	1.53
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C32	Larynx	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.09
C33-C34	Lung	0	0	1	1	1	1	2	15	9	15	13	8	8	5	3	1	0	83	7.46
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C38	Mediastinum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C40-C41	Bone	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	3	0.27
C43-C44	Skin	0	0	0	2	0	1	1	3	2	1	0	0	2	0	1	0	0	13	1.17
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	2	0.18
C49	Connective tissue	1	0	1	1	1	2	0	1	1	0	1	0	0	0	0	0	0	9	0.81
C50	Breast	0	0	8	23	51	44	69	73	66	46	28	15	16	1	4	4		448	40.25
C51	Vulva	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	3	0.27
C52	Vagina	0	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	3	0.27

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C53	Cervix	0	0	2	4	8	7	3	5	9	8	6	4	1	0	3	0	0	60	5.39
C54	Corpus uteri	0	0	1	0	1	2	5	5	9	7	5	3	3	0	0	0	0	41	3.68
C55	Uterus	0	0	1	0	0	0	0	1	0	2	0	1	0	0	0	0	0	5	0.45
C56	Ovary	0	2	0	4	3	1	4	5	5	3	1	3	2	1	0	0	0	34	3.05
C57	Other female genital organs	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.09
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C62	Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	0	0	0	0	1	1	1	2	0	1	1	0	1	0	0	8	0.72
C66	Ureter	0	0	0	0	0	0	1	0	0	0	2	1	1	0	0	0	0	5	0.45
C67	Bladder	0	0	0	0	0	0	0	0	0	3	0	2	2	0	0	0	0	7	0.63
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye and Adnexa	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.09
C70-C71	Brain	0	1	1	0	0	0	0	3	1	0	1	0	0	0	0	0	0	7	0.63
C72	Spinal cord and CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	1	4	13	14	17	7	15	8	5	7	3	2	2	0	0	0	0	98	8.81
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.09
C75	Other and endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other and ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C79	Unknown primary site	0	0	0	0	1	0	0	2	4	3	0	0	0	0	0	0	0	10	0.90
C81	Hodgkin's disease	3	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	6	0.54
C82	Follicular NHL	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	2	0.18
C83	Diffuse NHL	0	1	1	2	2	1	0	2	0	3	2	3	0	2	1	0	0	20	1.80
C84	Peripheral and cutaneous T-cell lymphoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C85	Other and unspecified type of NHL	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	4	0.36
C90	Multiple myeloma	0	0	0	0	0	1	0	1	1	1	0	1	0	0	0	0	0	5	0.45
C91	Lymphoid leukemia	0	0	0	1	0	0	0	1	0	1	0	0	1	0	0	0	0	4	0.36
C92	Myeloid leukemia	0	0	0	0	1	1	2	0	1	1	0	0	0	0	0	0	0	6	0.54
C95	Leukemia of unspecified cell type	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
D05	Ductal carcinoma in situ of breast	0	0	1	0	1	12	13	5	7	6	2	2	1	1	1	0	0	52	4.67
D46	Myelodysplastic syndrome	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
All ICD Group		6	10	32	59	99	92	134	149	152	141	88	57	47	21	20	6	0	1,113	100.00

A Report on Cancer Survival in Wattanosoth Cancer Hospital

This report on cancer survival is based on an analysis of data of top 3 common cancers (i.e., breast, colorectal and lung cancer) in Wattanosoth Cancer Hospital (WSH). The data has been collected by the hospital tumor registry. The cancer patients were diagnosed during a 12-month period from January 1st to December 31st, 2013. All of them received treatment at WSH and were prospectively followed-up up to December 31st, 2018 (5-year follow-up period).

Survival rates were estimated by Kaplan-Meier method. The survival rates of subgroups of cancer patients categorized by age (aged ≤ 50 and > 50 years old), sex (male and female) and stage of cancer at diagnosis (stage 1 - 4) were analyzed for comparison.

As this report is hospital registry-based cancer survival analysis, the study may have limitations related to endpoint data and sample size. The observed survival rates are estimated by method which cumulative probability of survival is calculated at consecutive one-month intervals after diagnosis. The information used included death from the cancer and other causes; lost to follow-up before observation period ended; and follow-up ends due to observation period ended. Therefore, survival estimated may be biased if the proportion of lost to follow-up or other causes of death is high.

Noted that survival rate estimated from small numbers of cases can provide misleading results and may have wide confidence intervals. In addition to compare survival rate between different groups, test for statistical significant may be misleading.

Breast cancer

Interval		Total	Deaths	Lost	Survival	Error	[95% Conf. Int.]	
0	1	202	1	62	0.9942	0.0058	0.9592	0.9992
1	2	139	1	21	0.9864	0.0096	0.9461	0.9966
2	3	117	1	5	0.9778	0.0128	0.9318	0.9929
3	4	111	0	9	0.9778	0.0128	0.9318	0.9929
4	5	102	0	13	0.9778	0.0128	0.9318	0.9929
5	6	89	1	88	0.9561	0.0249	0.8695	0.9857

Breast Cancer Survival rate

202 cases were diagnosed breast cancer during January 1st to December 31st, 2013. At the time of diagnosis, 73 (36.1%) of them were at stage 1, 52 (25.7%) at stage 2, 37 (18.3%) at stage 3, 15 (7.4%) at stage 4 and 25 (12.3%) at unknown stage. Their average age was 54.6 years old (SD \pm 12.6). 85 (42.1%) of them aged \leq 50 years old and 117 (57.9%) aged $>$ 50 years old.

The median follow-up period of these breast cancer patients was 48 months (25th - 75th percentile: 9 - 60 months). During the 5-year follow-up period, 4 of them were dead and 110 were lost to follow-up.

Kaplan-Meier survival estimate




Figure 1. Overall observed survival rate of the breast cancer patients in WSH during 5-year follow-up period

The overall observed survival rate of the breast cancer patients at 5-year follow-up period was 95.5% (95%CI: 86.9 - 98.5) (Fig.1). The survival seems to have no difference between the age group of > 50 and ≤ 50 years old, of which the survival rate was 93.7% (95%CI: 79.4 - 98.2), and 98.5% (95%CI: 90.3 - 99.8) respectively (Fig. 2).

Kaplan-Meier survival estimates




Figure 2. Observed survival rate of the breast cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old

The observed survival of the early stage breast cancers, i.e., stage 1 and 2 was 100.0% and 97.0% respectively, while the survival of the late stages, i.e., stage 3 and 4 was 93.9% (95%CI: 64.1 to 99.1) and 90.9% (95%CI: 50.8 to 98.7) respectively (Fig. 3). The survival rate tends to be lower in the late stage breast cancers.




Figure 3. Observed survival rate of the breast cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1-4)

Colorectal Cancer Survival rate

84 cases were diagnosed colorectal cancer during January 1st to December 31st, 2013. At the time of diagnosis, 4 (4.7%) of them were at stage 1, 23 (27.4%) at stage 2, 41 (48.8%) at stage 3, 14 (16.6%) at stage 4 and 2 (2.4%) at unknown stage. Their average age was 61.3 years old (SD \pm 14.5). 20 (23.8%) of them aged \leq 50 years old and 64 (76.2%) aged $>$ 50 years old. Among of them, there were 46 (54.7%) males and 38 (45.2%) females.

The median follow-up period of these colorectal cancer patients was 11 months (25th - 75th percentile: 3 - 57 months). During the 5-year follow-up period, 5 of them were dead and 59 were lost to follow-up.

Colorectal cancer

Interval		Total	Deaths	Lost	Survival	Error	[95% Conf. Int.]	
0	1	84	0	42	1.0000	0.0000	.	.
1	2	42	1	8	0.9737	0.0260	0.8275	0.9963
2	3	33	2	3	0.9119	0.0488	0.7501	0.9708
3	4	28	2	3	0.8430	0.0650	0.6612	0.9320
4	5	23	0	3	0.8430	0.0650	0.6612	0.9320
5	6	20	0	20	0.8430	0.0650	0.6612	0.9320

The overall observed survival rate of the colorectal cancer patients at 5-year follow-up period was 84.3% (95%CI: 66.1 - 93.2) (Fig.1).

Kaplan-Meier survival estimate




Figure 1. Overall observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period

The survival among the male patients was 84.9% (95%CI: 60.2 - 94.9) and female was 84.0% (95%CI: 48.7 - 95.8) (Fig. 2).

Kaplan-Meier survival estimates




Figure 2. Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by gender (male and female)

The male patients seem to have lower observed survival rate. The survival seems to have no difference between the age group of > 50 and ≤ 50 years old, of which the survival rate was 83.9% (95%CI: 62.4 - 93.7) and 85.7% (95%CI: 33.4 - 97.8) respectively (Fig. 3).

Kaplan-Meier survival estimates




Figure 3. Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old

The observed survival of early stage colorectal cancers, i.e., stage 1 and 2 were 100.0%, while the survival of the late stages, i.e., stage 3 and 4 was 80.8% (95%CI: 51.3 - 93.4) and 50.0% (95%CI: 57.8 - 84.4) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced. Especially in the stage 4, the survival was substantially decreased.

Kaplan-Meier survival estimates




Figure 4. Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1 – 4)

Lung Cancer Survival rate

103 cases were diagnosed lung cancer during January 1st to December 31st, 2013. At the time of diagnosis, 12 (11.6%) of them were at stage 1, 3 (2.9%) at stage 2, 25 (24.2%) at stage 3, 58 (56.3%) at stage 4 and 5 (4.85%) at unknown stage. Their average age was 63.8 years old (SD \pm 11.1). 14 (13.5%) of them aged \leq 50 years old and 89 (86.4%) aged $>$ 50 years old. Among of them, there were 68 (66.0%) males and 35 (34.0%) females.

The median follow-up period of these lung cancer patients was 7 months (25th - 75th percentile: 2 - 18). During the 5-year follow-up period, 13 of them were dead and 83 were lost to follow-up.

Lung cancer

Interval		Total	Deaths	Lost	Survival	Error	[95% Conf. Int.]	
0	1	103	5	62	0.9306	0.0300	0.8412	0.9705
1	2	36	6	9	0.7533	0.0695	0.5850	0.8610
2	3	21	1	7	0.7103	0.0777	0.5271	0.8329
3	4	13	1	4	0.6457	0.0937	0.4325	0.7959
4	5	8	0	1	0.6457	0.0937	0.4325	0.7959
5	6	7	0	7	0.6457	0.0937	0.4325	0.7959

The observed survival rate of the lung cancer patients at 5-year follow-up period was 64.57% (95%CI: 43.3 - 79.6) (Fig.1).




Figure 1. Overall observed survival rate of the lung cancer patients in WSH during 5-year follow-up period

The survival seems to have no difference between male and female patients, of which the survival rate was 58.4% (95% CI: 31.3 - 71.9) and 75.4% (95%CI: 39.9 - 91.7) respectively (Fig. 2).

Kaplan-Meier survival estimates




Figure 2. Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by gender (male and female)

The survival of patients aged > 50 and ≤ 50 years old was 68.5% (95%CI: 49.3 - 81.6) and 0.0% respectively (Fig. 3).

Kaplan-Meier survival estimates




Figure 3. Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old

The observed survival rate of early stage lung cancers, i.e., stage 1 and 2 was 87.5% (95%CI: 38.7 - 98.1) and 0.0% respectively while the survival of late stages, i.e., stage 3 and 4 was 46.4% (95%CI: 0.9 - 88.3) and 17.7% (95%CI: 1.4 - 49.3) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced.

Kaplan-Meier survival estimates




Figure 4. Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1 – 4)

BANGKOK HOSPITAL
HEART HOSPITAL
CANCER HOSPITAL
INTERNATIONAL HOSPITAL

CLIVA
TRANSITIONAL CARE HOSPITAL

สมิติเวช สุขุมวิท
SAMITVEJ SUKHUMVIT

สมิติเวช Children's HOSPITAL

สมิติเวช ศรีนครินทร์
SAMITVEJ SRINAKARIN

สมิติเวช สุขุมวิท
SAMITVEJ SUKHUMVIT

สมิติเวช ธนบุรี
SAMITVEJ THONBURI

BNH HOSPITAL
โรงพยาบาลบีเอ็นเอช

PHYATHAI HOSPITAL
โรงพยาบาลฟายไธ

PHYATHAI HOSPITAL
โรงพยาบาลฟายไธ

PHYATHAI HOSPITAL
โรงพยาบาลฟายไธ

PHYATHAI HOSPITAL
โรงพยาบาลฟายไธ

Paolo Hospital
โรงพยาบาลเปาโล

Paolo Hospital
โรงพยาบาลเปาโล

Paolo Hospital
โรงพยาบาลเปาโล

Paolo Hospital
โรงพยาบาลเปาโล

BANGKOK HOSPITAL
SARANANCH

โรงพยาบาลเทพาพร
TAPAKORN HOSPITAL

BANGKOK HOSPITAL
MUANGRAJ

BANGKOK HOSPITAL
PHETCHABURI

BANGKOK HOSPITAL
HUA HIN

BANGKOK HOSPITAL
SAMUI

BANGKOK HOSPITAL
SURAT

BANGKOK HOSPITAL
PHUKET

โรงพยาบาลสิริโรจน์
Siriraj International Hospital

โรงพยาบาลศิริราช
SIRIRAJ HOSPITAL

BANGKOK HOSPITAL
HAT YAI

BANGKOK HOSPITAL
CHIANG MAI

BANGKOK HOSPITAL
CHIANG RAI

BANGKOK HOSPITAL
PHITSANULOK

Paolo Hospital
โรงพยาบาลเปาโล

Paolo Hospital
โรงพยาบาลเปาโล

BANGKOK HOSPITAL
UDON

BANGKOK HOSPITAL
KHON KAEN

BANGKOK HOSPITAL
RATCHASIMA

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BANGKOK HOSPITAL
PAKCHONG

BDMS

Bangkok Dusit Medical Services

HOSPITAL :

BANGKOK HOSPITAL

สมิติเวช
SAMITVEJ

BNH HOSPITAL
โรงพยาบาลบีเอ็นเอช

PHYATHAI HOSPITAL
โรงพยาบาลฟายไธ

Paolo Hospital
โรงพยาบาลเปาโล

ROYAL BANGKOK HOSPITAL

NON HOSPITAL :

Health

MEDIC PHARMA

ANB LABORATORIES

SAVE DRUG

BANGKOK HELICOPTER SERVICES

BANGKOK HEALTH INSURANCE

GREENLINE SYNERGY

2 Soi Soonvijai 7, New Petchburi Rd., Huaykwang, Bangkok 10310 Thailand

Tel: 0 2310 3000, +662 BANGKOK or 1719 (local calls only) Fax: 0 2318 1546

www.wattanosothcancerhospital.com

0 2310 3088

0 2310 3327